, Columnist
Valeant's 'Significant Seven' Aren't Quite Magnificent
The company's roster of new drugs is encouraging, but only goes so far.
This article is for subscribers only.
Don't get too close -- you might scare them -- but Valeant Pharmaceuticals International Inc. shares are up more than 50 percent over the past two months.
That's not quite as impressive as it sounds, considering the company's 91 percent share-price drop from a 2015 peak and its $26 billion in debt. But management deserves credit for cutting some debt in 2017 and shifting other obligations into the 2020s.